Media.Player

Antisense Oligonucleotide Therapy for B Cell Mediated Cancers

Technology Benefits

Targets leukemia cells Conjugated for antisense oligonucleotide Targets precursor B cells Monoclonal antibody

Technology Application

Leukemia B cell mediated cancers, diseases and disorders

Detailed Technology Description

Antisense compounds have been used to modulate protein expression by binding to a target mRNA encoding the protein. Application of oligonucleotide-based technologies in cancer is promising but has had limited success in vivo due to the ineffective cell-targeting. Better targeting is needed to improve therapeutic efficacy of oligonucleotide-based cancer therapies in vivo. Researchers at the University of California, Davis have developed a precursor B cell (pre-B) acute lymphoblastic leukemia (ALL) cell targeting compound by directly conjugating an antisense oligonucleotide with an anti-CD22 antibody. This method specifically targets a transcription factor identified to be involved in pre-B ALL cell survival. In-vivo therapeutic efficacy has been successfully tested in pre-B ALL xenograft mouse models and Reh cell line, as well as patient-derived leukemia cells. Utilizing this method also provides new opportunities to treat and target B cells associated with leukemia, lymphoma and autoimmune disorders.

Application No.

9714288

Others

Additional Technologies by these Inventors

• Antibody Targeted Therapy for Lung and Prostate Tumors
• Fermented Wheat Germ Extract And Its Purified Low Molecular Weights Proteins For Treatment Of Lung Cancer
• Novel Methods and Devices for Bacteriophage Detection
• Methods for Selecting and Identifying Cancer Stem Cells
• Antimicrobial Particle with Affinity for Diverse Bacteria and Bacterial Films

Tech ID/UC Case

29215/2014-686-0

Related Cases

2014-686-0

*Abstract

Researchers at the University of California, Davis have developed a targeted therapy using an antisense oligonucleotide (ASO) to treat precursor B cell (pre-B) acute lymphoblastic leukemia (ALL).

*IP Issue Date

Jul 25, 2017

*Principal Investigator

Name: Nitin Nitin

Department:

Name: Noriko Satake

Department:

Name: Joseph Tuscano

Department:

Name: Shuling Guo

Department:

Name: Michael Oestergaard

Department:

Name: Punit Seth

Department:

Country/Region

USA